Fresenius Medical Care AG & Co. (NYSE:FMS) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, ValuEngine reports.

A number of other equities analysts have also commented on FMS. Royal Bank of Canada restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday, August 19th. JPMorgan Chase & Co. restated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research report on Thursday, August 29th. DZ Bank restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research report on Wednesday, October 30th. Finally, Redburn Partners restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $45.81.

NYSE:FMS opened at $36.39 on Tuesday. The firm has a market cap of $22.19 billion, a PE ratio of 16.03, a price-to-earnings-growth ratio of 3.65 and a beta of 1.46. Fresenius Medical Care AG & Co. has a 12 month low of $30.99 and a 12 month high of $42.75. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 0.75. The company’s 50-day moving average price is $35.64 and its two-hundred day moving average price is $35.97.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.08. The firm had revenue of $4.91 billion for the quarter, compared to analyst estimates of $4.72 billion. Fresenius Medical Care AG & Co. had a net margin of 7.47% and a return on equity of 9.92%. On average, research analysts expect that Fresenius Medical Care AG & Co. will post 2.44 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. NEXT Financial Group Inc bought a new position in shares of Fresenius Medical Care AG & Co. in the second quarter worth about $29,000. Old North State Trust LLC bought a new position in shares of Fresenius Medical Care AG & Co. in the third quarter worth about $29,000. Ashburton Jersey Ltd bought a new position in shares of Fresenius Medical Care AG & Co. in the second quarter worth about $39,000. Tower Research Capital LLC TRC raised its stake in shares of Fresenius Medical Care AG & Co. by 212.5% in the second quarter. Tower Research Capital LLC TRC now owns 1,078 shares of the company’s stock worth $42,000 after acquiring an additional 733 shares during the last quarter. Finally, Whittier Trust Co. bought a new position in shares of Fresenius Medical Care AG & Co. in the third quarter worth about $46,000. 1.40% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Story: What does an outperform rating mean?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.